Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA

Summary

Heterozygous mutations in MYH9, which encodes non-muscle myosin heavy chain IIA (MHC-IIA),result in autosomal dominant inherited MYH9-related disorders characterised by macrothrombocytopenia, granulocyte inclusions, variable sensorineural deafness, cataracts and nephritis. MHC-IIA is assembled into a complex consisting of two pairs of light chains and two heavy chains, where the latter contain a neck region, SH3-like, motor and rod domains. We describe a patient with a Trp33Cys missense mutation in the SH3-like domain of MHC-IIA. Abnormal platelet function was observed using platelet aggregometry with the agonists epinephrine and adenosine diphosphate (ADP). Patient granulocytes and megakaryocytes, but not platelets, contained abnormal MHC-IIA inclusions visualised by confocal immunofluorescence or electron microscopy. Megakaryocytes grown in culture were smaller and contained hypolobulated nuclei compared to controls. Bone marrow-derived megakaryocytes revealed a preponderance of immature forms, the presence of structurally diverse inclusion bodies, and frequent emperipolesis as assessed by electron microscopy. Platelets and leukocytes contained indistinguishable amounts of total MHCIIA determined by immunoblotting. Molecular modelling studies indicated that mutation of Trp33 destabilises the interface between the SH3-like and motor domain of MHC-IIA, which is close to previously described motor domain mutations, implying an important structural and/or functional role for this region in MHC-IIA.

Keywords

Inherited macrothrombocytopenia - MYH9-related disorder - megakaryocytes - emperipolesis - myosin IIA

• References

• 1 Seri M, Cusano R, Gangarossa S. et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/ Fechtner Syndrome Consortium. Nat Genet 2000; 26: 103-105.
• 2 Kelley MJ, Jawien W, Ortel TL. et al. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 2000; 26: 106-108.
• 3 Heath KE, Campos-Barros A, Toren A. et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001; 69: 1033-1045.
• 4 Kunishima S, Kojima T, Matsushita T. et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001; 97: 1147-1149.
• 5 Seri M, Pecci A, Di Bari F. et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003; 82: 203-215.
• 6 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35: 189-203.
• 7 Kunishima S, Matsushita T, Kojima T. et al. Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab Invest 2003; 83: 115-122.
• 8 Berg JS, Powell BC, Cheney RE. A millennial myosin census. Mol Biol Cell 2001; 12: 780-794.
• 9 Leal A, Endele S, Stengel C. et al. A novel myosin heavy chain gene in human chromosome 19q13.3. Gene 2003; 312: 165-171.
• 10 Hodge T, Cope MJ. A myosin family tree. J Cell Sci 2000; 113 Pt (19) 3353-3354.
• 11 Marigo V, Nigro A, Pecci A. et al. Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. Genomics 2004; 83: 1125-1133.
• 12 Maupin P, Phillips CL, Adelstein RS. et al. Differential localization of myosin-II isozymes in human cultured cells and blood cells. J Cell Sci 1994; 107: 3077-3090.
• 13 Conti MA, Even-Ram S, Liu C. et al. Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice. J Biol Chem 2004; 279: 41263-41266.
• 14 Tullio AN, Accili D, Ferrans VJ. et al. Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc Natl Acad Sci USA 1997; 94: 12407-12412.
• 15 Clark K, Langeslag M, Figdor CG. et al. Myosin II and mechanotransduction: a balancing act. Trends Cell Biol 2007; 17: 178-186.
• 16 Matsumura F. Regulation of myosin II during cytokinesis in higher eukaryotes. Trends Cell Biol 2005; 15: 371-377.
• 17 Chen Z, Naveiras O, Balduini A. et al. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 2007; 110: 171-179.
• 18 Chang Y, Aurade F, Larbret F. et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 2007; 109: 4229-4236.
• 19 Leon C, Eckly A, Hechler B. et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 2007; 110: 3183-3191.
• 20 Ono A, Westein E, Hsiao S. et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood 2008; 112: 90-99.
• 21 Franke JD, Dong F, Rickoll WL. et al. Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly. Blood 2005; 105: 161-169.
• 22 Niederman R, Pollard TD. Human platelet myosin. II. In vitro assembly and structure of myosin filaments. J Cell Biol 1975; 67: 72-92.
• 23 Pecci A, Panza E, Pujol-Moix N. et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29: 409-417.
• 24 Burt RA, Joseph JE, Milliken S. et al. Description of a novel mutation leading to MYH9-related disease. Thromb Res 2008; 122: 861-863.
• 25 Miyajima Y, Kunishima S. Identification of the first in cis mutations in MYH9 disorder. Eur J Haematol 2009; 82: 288-291.
• 26 Miyazaki K, Kunishima S, Fujii W. et al. Identification of three in-frame deletion mutations in MYH9 disorders suggesting an important hot spot for small rearrangements in MYH9 exon 24. Eur J Haematol 2009; 83: 230-234.
• 27 Provaznikova D, Geierova V, Kumstyrova T. et al. Clinical manifestation and molecular genetic characterization of MYH9 disorders. Platelets 2009; 20: 289-296.
• 28 Calaminus SD, Auger JM, McCarty OJ. et al. MyosinIIa contractility is required for maintenance of platelet structure during spreading on collagen and contributes to thrombus stability. J Thromb Haemost 2007; 05: 2136-2145.
• 29 Canobbio I, Noris P, Pecci A. et al. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost 2005; 03: 1026-1035.
• 30 Kunishima S, Matsushita T, Kojima T. et al. Identification of six novel MYH9 mutations and genotypephenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions. J Hum Genet 2001; 46: 722-729.
• 31 Lo B, Li L, Gissen P. et al. Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 2005; 106: 4159-4166.
• 32 Dominguez R, Freyzon Y, Trybus KM. et al. Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain: visualization of the pre-power stroke state. Cell 1998; 94: 559-571.
• 33 Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
• 34 Kunishima S, Hamaguchi M, Saito H. Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders. Blood 2008; 111: 3015-3023.
• 35 Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123: 172-183.
• 36 Noris P, Spedini P, Belletti S. et al. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med 1998; 104: 355-360.
• 37 Deutsch S, Rideau A, Bochaton-Piallat ML. et al. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. Blood 2003; 102: 529-534.
• 38 Pecci A, Canobbio I, Balduini A. et al. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum Mol Genet 2005; 14: 3169-3178.
• 39 Pujol-Moix N, Kelley MJ, Hernandez A. et al. Ultrastructural analysis of granulocyte inclusions in genetically confirmed MYH9-related disorders. Haematologica 2004; 89: 330-337.
• 40 Peterson LC, Rao KV, Crosson JT. et al. Fechtner syndrome--a variant of Alport’s syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985; 65: 397-406.
• 41 Centurione L, Di Baldassarre A, Zingariello M. et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood 2004; 104: 3573-3580.
• 42 Cashell AW, Buss DH. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states. Ann Hematol 1992; 64: 273-276.
• 43 Schmitt A, Jouault H, Guichard J. et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000; 96: 1342-1347.
• 44 Avci Z, Turul T, Catal F. et al. Thrombocytopenia and emperipolesis in a patient with hepatitis a infection. Pediatr Hematol Oncol 2002; 19: 67-70.
• 45 Bobik R, Dabrowski Z. Emperipolesis of marrow cells within megakaryocytes in the bone marrow of sublethally irradiated mice. Ann Hematol 1995; 70: 91-95.
• 46 Lee KP. Emperipolesis of hematopoietic cells within megakaryocytes in bone marrow of the rat. Vet Pathol 1989; 26: 473-478.
• 47 McGarry MP, Reddington M, Jackson CW. et al. Increased incidence and analysis of emperipolesis in megakaryocytes of the mouse mutant gunmetal. Exp Mol Pathol 1999; 66: 191-200.
• 48 Eckly A, Strassel C, Freund M. et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. Blood 2009; 113: 3182-3189.
• 49 Pecci A, Malara A, Badalucco S. et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009; 102: 90-96.
• 50 Chen Z, Shivdasani RA. Regulation of platelet biogenesis: insights from the May-Hegglin anomaly and other MYH9-related disorders. J Thromb Haemost 2009; 07 (Suppl. 01) 272-276.